Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01458340 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT01458340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01458340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead sponsor
Theravance Biopharma
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
November 30, 2013
Enrollment
295 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

adhd, attention-deficit/hyperactivity disorder